亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

拉帕替尼

 
 
單價(jià) 面議對(duì)比
詢(xún)價(jià) 暫無(wú)
發(fā)貨 山東濟(jì)南市付款后3天內(nèi)
品牌 惠誠(chéng)
過(guò)期 長(zhǎng)期有效
更新 2017-07-19 10:00
 

濟(jì)南惠誠(chéng)醫(yī)藥科技有限公司

企業(yè)會(huì)員第10年
資料未認(rèn)證
保證金未繳納
詳細(xì)說(shuō)明

中文名稱(chēng): 拉帕替尼

中文同義詞: N-[3--4-[(3-氟苯基)甲氧基]苯基]-6-[5-[(2-甲磺酰乙基氨基)甲基]-2-呋喃基]喹唑啉-4-;拉帕替尼;拉帕替尼堿;二***磺酸拉帕替尼中間體;GW2016 LAPATINIB;GW 572016LAPATINIB拉帕替尼;拉帕替尼, 99+%;GW-572016; TYKERB

英文名稱(chēng): Lapatinib

英文同義詞: lapatinib;n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-;Lapatinib(TINIBS);N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine;Lapatinib base N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-Quinazolinamine;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline

CAS號(hào): 231277-92-2

分子式: C29H26ClFN4O4S

分子量: 581.0575432

相關(guān)類(lèi)別: TINIBS替尼類(lèi)產(chǎn)品(Anti-cancer);Molecular Targeted Antineoplastic;anti-neoplastic;抗癌藥物;Pharmaceutical intermediate;APIs;API;抗腫瘤;二對(duì)***磺酸拉帕替尼,Lapatinib ditosylate;原料藥;原料藥中間體;Lapatinib;拉帕替尼;醫(yī)藥中間體;Anti-cancer&immunity;蛋白酪氨酸激酶;抗腫瘤藥物;中間體;抗癌類(lèi);抗腫瘤類(lèi);小分子抑制劑;Inhibitors;小分子抑制劑,天然產(chǎn)物;堿基形式;醫(yī)藥原料

用途:乳腺癌靶向治療新藥

舉報(bào)收藏 0評(píng)論 0
更多>本企業(yè)其它產(chǎn)品
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |